2-[18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography in Staphylococcus aureus Bacteremia: Do We Already Know Enough?

Abstract:

TO THE EDITOR—We read with great interest the Viewpoint article by Thottacherry and Cortés-Penfield in which they summarize the evidence for 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) in Staphylococcus aureus bacteremia (SAB)[1]. They identified 7 studies that showed beneficial effects of 18F-FDGPET/CT, including frequent detection of metastatic infections, more source control procedures, and lower rates of infection relapse and mortality. Based on these studies, the authors conclude that 18F-FDG-PET/CT has demonstrated its value in SAB management and advocate that Medicare expand access for this procedure. Although we agree that 18F-FDG-PET/CT is a potentially useful diagnostic procedure in patients with SAB, we think that the authors’ conclusions are not fully justified by the available evidence. First, all studies on 18F-FDG-PET/CT …

Año de publicación:

2022

Keywords:

Fuente:

google